Loading...
•
Dec 31, 2025
Prime Medicine Q4 2025 Earnings Report
Prime Medicine reported its fourth quarter and full year 2025 financial results, highlighting clinical progress in its Prime Editing platform and a cash runway extending into 2027.
Key Takeaways
Prime Medicine focused on advancing its in vivo liver franchise and engaging with the FDA for PM359 in CGD. While the company reported a net loss for the year, it maintained a solid cash position of $191.4 million and is preparing for multiple IND/CTA filings in 2026.
On track to file IND/CTA for Wilson Disease in 1H 2026 and AATD in mid-2026.
Ongoing engagement with the FDA for PM359 in CGD with potential for accelerated approval.
Cash, cash equivalents, investments, and restricted cash of $191.4 million provides runway into 2027.
Reported positive Phase 1/2 clinical data for PM359 in the New England Journal of Medicine.
Revenue by Segment
Forward Guidance
Prime Medicine expects its current cash position to fund operations into 2027, focusing on regulatory filings and clinical trial initiations.
Positive Outlook
- Cash runway extends into 2027.
- Planned IND/CTA filing for Wilson Disease in 1H 2026.
- Planned IND/CTA filing for AATD in mid-2026.
- Initial clinical data for WD and AATD expected in 2027.
- Potential for accelerated approval path for PM359 in CGD.
Challenges Ahead
- Company remains pre-revenue with significant net losses.
- Dependence on successful regulatory alignment with the FDA.
- R&D costs remain high due to platform advancement.
- Workforce reductions occurred in 2025 to manage costs.
- Clinical success for liver programs is not yet guaranteed.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...